Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 990-992

  Oki, Yasuhiro ^a   Copeland, Amanda ^a   Romaguera, Jorge ^a   Fayad, Luis ^a   Fanale, Michelle ^a   Faria, Silvana De Castro ^a   Medeiros, L Jeffrey ^a   Ivy, Percy ^b   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN D1; HEAT SHOCK PROTEIN 90; KI 67 ANTIGEN; PROTEIN KINASE B; TANESPIMYCIN;

ADULT; AGED; ARTIFICIAL VENTILATION; CLASSICAL HODGKIN LYMPHOMA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LETTER; MALE; MANTLE CELL LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; BENZOQUINONES; DRUG TOXICITY; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84859933960     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631236     Document Type: Letter

References (14)

1. Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-549.
2. Valbuena JR, Rassidakis GZ, Lin P, et al. Expression of heat-shock protein-90 in non-Hodgkin 's lymphomas. Mod Pathol 2005;18:1343-1349. (Pubitemid 41348653)
3. Goetz MP, Toft DO, Ames MM, et al. Th e Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-1176. (Pubitemid 37039035)
4. Bonvini P, Dalla Rosa H, Vignes N, et al. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004;64:3256-3264. (Pubitemid 38581430)
5. Bonvini P, Gastaldi T, Falini B, et al. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK( ) CD30( ) lymphoma cells by the Hsp90 antagonist 17- allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62:1559-1566. (Pubitemid 34407823)
6. Georgakis GV, Li Y, Rassidakis GZ, et al. Th e HSP90 inhibitor 17- AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 2006;34: 1670-1679. (Pubitemid 44838995)
7. Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-590. (Pubitemid 43166153)
8. Georgakis GV, Li Y, Younes A. Th e heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71. (Pubitemid 44337664)
9. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-1893. (Pubitemid 46211366)
10. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino- 17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-1782. (Pubitemid 46952945)
11. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152-4161. (Pubitemid 46211321)
12. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-1087. (Pubitemid 46202262)
13. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-6093. (Pubitemid 44703773)
14. Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011;152:367-379.